Skip to main content

Gene Therapy Turns Immune Cells

Breakthrough Gene Therapy Turns Immune Cells Against Cancer



A groundbreaking study led by researchers from Israel, the US, and China has developed a genetic method to reprogram immune cells, transforming them from cancer promoters into powerful tumor fighters. The findings, published by the Weizmann Institute of Science, could pave the way for new immunotherapy treatments for solid cancers.

Macrophages: The Double-Edged Sword of the Immune System


Macrophages are versatile immune cells that typically help the body fight infections and diseases. However, in many cancers, they switch sides, protecting tumors, aiding their growth, and even helping them spread.

“Macrophages are like the Swiss Army knife of the immune system—they can perform many functions, but in cancer, they’re hijacked to help tumors survive,” explained Prof. Ido Amit, lead researcher at Weizmann’s Systems Immunology Department.
Gene-Editing Breakthrough: The Zeb2 Switch

Using CRISPR-Cas9 gene editing and AI-powered single-cell analysis, the team analyzed human tumor samples and identified 120 genes linked to this harmful transformation. They discovered that Zeb2, a key gene, acts as a master switch:When active → Macrophages support cancer growth, When silenced → Macrophages revert to their natural tumor-fighting state. Further research revealed that Zeb2 alters the epigenome, turning off anti-cancer genes while activating those that help tumors thrive.

DNA Therapy Shows Promise in Shrinking Tumors


The team designed a custom DNA molecule that delivers a gene-silencing agent directly into macrophages. In mice with bladder cancer, injecting this molecule reprogrammed the macrophages, leading to significant tumor shrinkage.

Implications for Future Cancer Treatments


This discovery opens new possibilities for immunotherapy, offering a way to re-educate immune cells rather than just destroying them. The next step is human clinical trials to test the therapy’s effectiveness in cancer patients. “We’re turning the enemy into an ally—using the body’s own defenses to fight cancer from within,” said Amit.

This research could lead to more precise, less toxic cancer treatments, potentially improving outcomes for patients with solid tumors like bladder, breast, and lung cancers.

gene therapy, genetic engineering, CRISPR, gene editing, viral vectors, non-viral delivery, somatic gene therapy, germline modification, DNA repair, RNA therapeutics, gene silencing, genome integration, precision medicine, molecular medicine, genetic disorders, inherited diseases, transgene expression, therapeutic genes, biotechnology, personalized therapy

#GeneTherapy, #GeneticEngineering, #CRISPR, #GeneEditing, #DNARepair, #RNAi, #MolecularMedicine, #Biotech, #TherapeuticGenes, #GenomeTherapy, #PrecisionMedicine, #Genomics, #PersonalizedMedicine, #RareDiseaseResearch, #InheritedDiseases, #ViralVectors, #NonViralDelivery, #GeneSilencing, #SomaticTherapy, #FutureOfMedicine

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more